WebMar 15, 2024 · Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended December 31, … WebJun 10, 2024 · PTGX has a market capitalization of ~$590 million and cash on hand of ~$240 million. They have stated they have enough cash to fund pipeline programs through mid-2024. Their pipeline consists of ...
Protagonist Therapeutics Inc. Research & Ratings PTGX Barron
WebDec 2, 2024 · NEWARK, Calif., Dec. 2, 2024 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the selection of PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on intervention of the Interleukin-23 (IL-23) pathway, under the Company's collaboration … WebSep 17, 2024 · Protagonist Therapeutics, Inc. Sep 17, 2024, 07:00 ET. NEWARK, Calif., Sept. 17, 2024 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) … cyber security sacs
Biotech Stock Roundup: PTGX Gains on Study Data, BMRN …
WebMar 9, 2024 · Pipeline and regulatory updates from Protagonist (PTGX) and BioMarin (BMRN) are the key highlights from the biotech sector during the past week. WebAbout PTGX. Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to … WebApr 16, 2024 · A number of brokerages have recently weighed in on PTGX. ... Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, ... cheap spikes for clothes